The possible role of human papillomavirus infection in the development of lichen sclerosus
Corresponding Author
Jan Blaakaer DMSc
Department of Obstetrics and Gynaecology, Odense University Hospital, Odense, Denmark
Correspondence
Jan Blaakaer, dmsc
Skaering Egager 20
8250 Egaa
Denmark
E-mail: [email protected]
Search for more papers by this authorCorresponding Author
Jan Blaakaer DMSc
Department of Obstetrics and Gynaecology, Odense University Hospital, Odense, Denmark
Correspondence
Jan Blaakaer, dmsc
Skaering Egager 20
8250 Egaa
Denmark
E-mail: [email protected]
Search for more papers by this authorAbstract
Lichen sclerosus (LS) is a chronic inflammatory skin disease of unknown origin predominantly affecting the anogenital area that causes pruritus and pain and is associated with an increased risk of malignancy. In some cases, LS vanishes after application of imiquimod, raising the question whether human papillomavirus (HPV) may have an etiopathogenic role in anogenital LS. The databases MEDLINE and Embase were systematically searched using the PRISMA guidelines. Twenty-seven papers were included that reported the prevalence of HPV in LS and in LS associated with neoplasia. HPV was identified in 0–80% (median 22%) of all LS cases. The prevalence of HPV was higher among male patients with LS (median 29%) than among female patients (median 8%). HPV16 was the most prevalent genotype, but the distribution of genotypes indicates that even low-risk HPV can cause LS. The diverging detection rates are probably due to small sample sizes in the reviewed papers and different detection methods. Factors possibly underestimating the prevalence of HPV are a selective search for high-risk HPV, DNA destruction in fixed tissue, focally residing HPV, and possibly a clearing of HPV before the time of biopsy. Seventy-five percent of sexually active people acquire HPV during their lifetime, thus HPV alone is not a cause of LS. Genetic and immunological host factors and viral factors other than type are likely to contribute. Future studies should include patients with a short duration of symptoms, and biopsies should be multiple and fresh.
References
- 1Kirtschig G. Lichen sclerosus – presentation, diagnosis and management. Dtsch Arztebl Int 2016; 113: 337–343.
- 2Bunker CB, Shim TN. Male genital lichen sclerosus. Indian J Dermatol 2015; 60: 111–117.
- 3Sherman V, McPherson T, Baldo M, et al. The high rate of familial lichen sclerosus suggests a genetic contribution: an observational cohort study. J Eur Acad Dermatol Venereol 2010; 24: 1031–1034.
- 4Marren P, Yell J, Charnock FM, et al. The association between lichen sclerosus and antigens of the HLA system. Br J Dermatol 1995; 132: 197–203.
- 5Cooper SM, Ali I, Baldo M. The association of lichen sclerosus and erosive lichen planus of the vulva with autoimmune disease: a case-control study. Arch Dermatol 2008; 144: 1432–1435.
- 6Higgins CA, Cruickshank ME. A population-based case–control study of aetiological factors associated with vulval lichen sclerosus. J Obstet Gynaecol 2012; 32: 271–275.
- 7Regauer S. Immune dysregulation in lichen sclerosus. Eur J Cell Biol 2005; 84: 273–277.
- 8Aidé S, Lattario FR, Almeida G, et al. Epstein-barr virus and human papillomavirus infection in vulvar lichen sclerosus. J Low Genit Tract Dis 2010; 14: 319–322.
- 9Vignale R, Acosta G, Paciel J, et al. Presencia del virus del papiloma humano en lesiones de liquen escleroso y atrófico vulvar. Estudio por inmunohistoquímica e hibridización in situ. Actas Dermosifiliogr 2002; 93: 389–392.
- 10Kiene P, Milde-Langosch K, Löning T. Human papillomavirus infection in vulvar lesions of lichen sclerosus et atrophicus. Arch Dermatol Res 1991; 283: 445–448.
- 11Haefner HK, Tate JE, McLachlin CM, et al. Vulvar intraepithelial neoplasia – age, morphological phenotype, papillomavirus DNA, and coexisting invasive carcinoma. Hum Pathol 1995; 26: 147–154.
- 12Kagie MJ, Kenter GG, Zomerdijk-Nooijen Y, et al. Human papillomavirus infection in squamous cell carcinoma of the vulva, in various synchronous epithelial changes and in normal vulvar skin. Gynecol Oncol 1997; 67: 178–183.
- 13Drut RM, Gomez MA, Drut R, et al. Human papillomavirus is present in some cases of childhood penile lichen sclerosus – an in situ hybridization and SP-PCR study. Pediatr Dermatol 1998; 15: 85–90.
- 14Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J Am Acad Dermatol 1999; 41: 911–914.
- 15von Krogh G, Dahlman-Ghozlan K, Syrjänen S. Potential human papillomavirus reactivation following topical corticosteroid therapy of genital lichen sclerosus and erosive lichen planus. J Eur Acad Dermatol Venereol 2002; 16: 130–133.
- 16Regauer S, Reich O, Beham-Schmid C. Monoclonal γ-T-cell receptor rearrangement in vulvar lichen sclerosus and squamous cell carcinomas. Am J Pathol 2002; 160: 1035–1045.
- 17Perceau G, Derancourt C, Clavel C, et al. Lichen sclerosus is frequently present in penile squamous cell carcinomas but is not always associated with oncogenic human papillomavirus. Br J Dermatol 2003; 148: 934–938.
- 18Powell J, Strauss S, Gray J, et al. Genital carriage of human papilloma virus (HPV) DNA in prepubertal girls with and without vulval disease. Pediatr Dermatol 2003; 20: 191–194.
- 19Nasca MR, Innocenzi D, Micali G. Association of penile lichen sclerosus and oncogenic human papillomavirus infection. Int J Dermatol 2006; 45: 681–683.
- 20van Seters M, ten Kate FJ, van Beurden M, et al. In the absence of (early) invasive carcinoma, vulvar intraepithelial neoplasia associated with lichen sclerosus is mainly of undifferentiated type: new insights in histology and aetiology. J Clin Pathol 2007; 60: 504–509.
- 21Prowse DM, Ktori EN, Chandrasekaran D, et al. Human papillomavirus-associated increase in p16INK4A expression in penile lichen sclerosus and squamous cell carcinoma. Br J Dermatol 2008; 158: 261–265.
- 22Gardner JA, Cooper K, Rajendran V, et al. Investigation of human papillomavirus infections in vulvar intraepithelial neoplasia by polymerase chain reaction, chomogenic in situ hybridization and immunohistochemistry. Lab Invest 2011; 91: 246A–247A.
- 23Guerrero D, Guarch R, Ojer A, et al. Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer. Int J Cancer 2011; 128: 2853–2864.
- 24Paolino G, Panetta C, Cota C, et al. Lichen Sclerosus and the risk of malignant progression: a case series of 159 patients. G. Ital Dermatol Venereol 2013; 148: 673–678.
- 25Guerrero-Setas D, Perez-Janices N, Ojer A, et al. Differential gene hypermethylation in genital lichen sclerosus and cancer: a comparative study. Histopathology 2013; 63: 659–669.
- 26Shim T, De Koning M, Muneer A, et al. HPV in male genital lichen sclerosus, penile carcinoma in-situ and penile squamous cell carcinoma. J Invest Dermatol 2013; 133: S195.
- 27Shim TN, De Koning MN, Goolamali SI, et al. Prevalence of human papillomavirus in male genital lichen sclerosus, penile carcinoma in situ and penile carcinoma: correlation with p16INK4a expression and immune status. Br J Dermatol 2014; 171: 34–35.
- 28Hørding U, Junge J, Daugaard S, et al. Vulvar squamous cell carcinoma and papillomaviruses – indications for two different etiologies. Gynecol Oncol 1994; 52: 241–246.
- 29Lerma E, Matias-Guiu X, Soon JL, et al. Squamous cell carcinoma of the vulva – study of ploidy, HPV, p53, and pRb. Int J Gynecol Pathol 1999; 18: 191–197.
- 30Ueda Y, Enomoto T, Miyatake T, et al. Analysis of clonality and hpv infection in benign, hyperplastic, premalignant, and malignant lesions of the vulvar mucosa. Am J Clin Pathol 2004; 122: 266–274.
- 31van der Avoort IAM, Shirango H, Hoevenaars BM, et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int J Gynecol Pathol 2006; 25: 22–29.
- 32Skapa P, Zamecnik J, Hamsikova E, et al. Human papillomavirus (HPV) profiles of vulvar lesions. Possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination. Am J Surg Pathol 2007; 31: 1834–1843.
- 33van der Avoort IA, van de Nieuwenhof HP, Otte-Holler I, et al. High levels of p53 expression correlate with DNA aneuploidy in (pre)malignancies of the vulva. Hum Pathol 2010; 41: 1475–1485.
- 34Zhang Y, Fu Q, Zhang X. The presence of human papillomavirus and Epstein-Barr virus in male Chinese lichen sclerosus patients: a single center study. Asian J Androl 2016; 18: 650–653.
- 35Ansink AC, Krul MR, De Weger RA, et al. Human papillomavirus, lichen sclerosus, and squamous cell carcinoma of the vulva – detection and diagnostic significance. Gynecol Oncol 1994; 52: 180–184.
- 36McNamara M, Batur P, Walsh JME, et al. HPV update: vaccination, screening, and associated disease. J Gen Intern Med 2016; 31: 1360–1366.
- 37Walhart T. Human papillomavirus biology, pathogenesis, and potential for drug discovery: a literature review for HIV nurse clinical scientists. J Assoc Nurses AIDS Care 2015; 26: 693–702.
10.1016/j.jana.2015.07.001 Google Scholar
- 38Bruni L, Diaz M, Castellsague X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789–1799.
- 39Hebnes JB, Olesen TB, Duun-Henriksen AK, et al. Prevalence of genital human papillomavirus among men in Europe: systematic review and meta-analysis. J Sex Med 2014; 11: 2630–2644.
- 40Van Doorslaer K, Chen Z, McBride AA. Detection and genotyping of human papillomaviruses from archival formalin-fixed tissue samples. Curr Protoc Microbiol 2016; 43: 14B.9.1–14B.9.20.
- 41Chung SH. Cervical cancer screening after perimenopause: how is human papillomavirus test performed? J Menopausal Med 2016; 22: 65–70.
10.6118/jmm.2016.22.2.65 Google Scholar
- 42Bilenchi R, Poggiali S, De Padove LA, et al. Human papillomavirus reactivation following topical tacrolimus therapy of anogenital lichen sclerosus. Br J Dermatol 2007; 156: 405–406.
- 43Dunne EF, Koch A. HPV vaccines for circumpolar health: summary of plenary session, “Opportunities for Prevention: global HPV Vaccine” and “Human Papillomavirus Prevention: The Nordic Experience”. Int J Circumpolar Health 2013; 72: 21070. https://org.doi.10.3402/ijch.v72i0.21070.
- 44Kai A, Lewis F. Long-term use of an ultrapotent topical steroid for the treatment of vulval lichen sclerosus is safe. J Obstet Gynaecol 2016; 36: 276–277.